New drug MK-4884 tested for safety in advanced cancers

NCT ID NCT07600749

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how the drug moves through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer cancer cholangiocarcinoma colorectal carcinoma gallbladder cancer neoplasm non-small cell lung carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

NEXT Oncology ( Site 0151)
RECRUITING

San Antonio, Texas, 78229, United States

Contact Phone: •••-•••-••••
National Cancer Center Hospital ( Site 0201)
RECRUITING

Chūō, Tokyo, 104-0045, Japan

Contact Phone: •••-•••-••••
Ospedale Regionale Bellinzona e Valli ( Site 0104)
RECRUITING

Bellinzona, Canton Ticino, 6500, Switzerland

Contact Phone: •••-•••-••••
Rabin Medical Center ( Site 0053)
RECRUITING

Petah Tikva, 4941492, Israel

Contact Phone: •••-•••-••••
Rambam Health Care Campus ( Site 0051)
RECRUITING

Haifa, 3109601, Israel

Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.